Journal of Medicinal Chemistry · 2010 · 24 citations · 41 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryNeuropharmacologyStructure-activity RelationshipsEnzyme InhibitionLigand BindingNeurochemical PharmacologyPotency OptimizationSerotonergic PharmacologyStructure-activity Relationship AnalysisChemical Structure-activity RelationshipsDopamine TransportersNorepinephrine Reuptake InhibitionNorepinephrine Transporter InhibitionReuptake Transporter InhibitionSelectivitySerotonergic Drug DiscoverySerotonin Transporter Pharmacology
Efforts to identify new selective and potent norepinephrine reuptake inhibitors (NRIs) for multiple indications by structural modification of the previous 3-(arylamino)-3-phenylpropan-2-olamine scaffold led to the discovery of a novel series of 1-(indolin-1-yl)-1-phenyl-3-propan-2-olamines (9). Investigation of the structure-activity relationships revealed that small alkyl substitution at the C3 position of the indoline ring enhanced selectivity for the norepinephrine transporter (NET) over the serotonin transporter (SERT). Several compounds bearing a 3,3-dimethyl group on the indoline ring, 9k, 9o,p, and 9s,t, exhibited potent inhibition of NET (IC(50) = 2.7-6.5 nM) and excellent selectivity over both serotonin and dopamine transporters. The best example from this series, 9p, a potent and highly selective NRI, displayed oral efficacy in a telemetric rat model of ovariectomized-induced thermoregulatory dysfunction, a mouse p-phenylquinone (PPQ) model of acute visceral pain, and a rat spinal nerve ligation (SNL) model of neuropathic pain.
41